Patent intelligence · DK
DK 0781560
Anvendelse af immunoglobulinpræparater til fremstilling af et medikament til oral indgivelse til behandling og forebyggelse
Anvendelse af immunoglobulinpræparater til fremstilling af et medikament til oral indgivelse til behandling og forebyggelse
Patent details — DK 0781560
- Jurisdiction
- DK
- Status
- expired
- Grant date
- Nov 13, 2000
- Expiration
- Nov 8, 2020
- Applicant
- BIOTEST PHARMA GMBH [DE]
- CPC classes
- A61K 31/ 44 A I, A61K 39/ 40 A I, A61K/3940, A61K31/44
Quick answer
DK 0781560 (Anvendelse af immunoglobulinpræparater til fremstilling af et medikament til oral indgivelse til behandling og forebyggelse) is held by BIOTEST PHARMA GMBH [DE]. Status: expired. Granted Nov 13, 2000. Expires Nov 8, 2020 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BIOTEST PHARMA GMBH [DE]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 31/ 44 A I, A61K 39/ 40 A I, A61K/3940, A61K31/44, A61K39/40
More from BIOTEST PHARMA GMBH [DE]
Related pharmaceutical patents in our USPTO index.
-
CA 1341505
PREPARATION D'IMMUNOGLOBULINE POLYCLONALE CONTENANT DE L'IGM, AUX FINS D'ADMINISTRATION INTRAVEINEUSE, AINSI QUE SA METHODE DE FABRICATION
expired -
AT E191006
MENSCHLICHE MONOKLONALE ANTIKÖRPER GEGEN RHESUS D UND ZELLINIEN DIE DIESE PRODUZIEREN
expired -
DE 69229278
HUMANISIERTER B-B10, EIN ANTI-IL-2-REZEPTOR-ANTIKÖRPER
expired
Frequently asked questions
What is US patent 0781560?
DK 0781560 (Anvendelse af immunoglobulinpræparater til fremstilling af et medikament til oral indgivelse til behandling og forebyggelse) is held by BIOTEST PHARMA GMBH [DE]. Status: expired. Granted Nov 13, 2000. Expires Nov 8, 2020 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns DK 0781560?
BIOTEST PHARMA GMBH [DE] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 4 pharmaceutical patents for this assignee.
When does DK 0781560 expire?
Our index shows an expiration date of Nov 8, 2020 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.